Nureca Limited Reports 87% Growth in Q4 FY25, Expands Reach with Swiggy, and Outlines Strategic Priorities for FY 26

Nureca Limited, a leading player in the home healthcare and wellness industry, announced its financial results for the fourth quarter and year ended March 31, 2025. The company reported an 87% increase in revenue to ¥31.74 crore in Q4 FY25 and a 19.3% increase in revenue to ¥109.66 crore for the full year FY25. EBIDTA improved by 156% to ¥3.2 crore in Q4 FY25 and 1489% to ¥4.9 crore for the full year FY25. Nureca Technologies Private Limited, the manufacturing arm of Nureca Limited, completed its annual registration with the U.S. FDA for its 510(k)-exempt medical devices. The company is also expanding its Direct-to-Consumer (D2C) channel and has partnered with Swiggy instamart for quick commerce. Nureca's strategic priorities for FY26 include manufacturing expansion, quick commerce leadership, innovation pipeline, and export growth.